Rising prevalence of non-small cell lung cancer and increased investment in Research & Development (R&D) of new therpaies for the disease is driving market revenue growth.
Rising prevalence of non-small cell lung cancer and increased investment in Research & Development (R&D) of new therpaies for the disease is driving market revenue growth
The global Non-Small Cell Lung Cancer (NSCLC) market size is expected to reach USD 13.68 Billion in 2030 and register a revenue CAGR of 6.5% over the forecast period, according to latest report by Reports and Data. Excessive consumption of tobacco, increase in active and passive smokers, and exposure to high levels of pollution are key factors propelling market revenue growth of NSCLC.
NSCLC accounts for a significant percentage of lung cancer cases across the world, and this high number has encouraged market players to focus on development of new therapies and improving efficacy of existing medicines for the disease. Lung cancer is one of the most common malignancies and results in a significant number of deaths globally. This has created a need to treat the disease and reduce mortality rate.
Expansion of NSCLC market is further aided by an increase in frequency of diagnosis of non-small cell lung cancer and increased awareness regarding the disease in developed and emerging countries. This, combined with increased investment in R&D by pharmaceutical companies and rapid adoption of new and better healthcare technologies is driving market revenue growth of NSCLC market. Moreover, increased adoption of immunotherapy in developing countries due to improved patient outcomes because of efficient treatment is expected to drive market revenue growth.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/1475
Some Key Highlights from the Report
- In February 2021, the U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor Libtayo for first-line treatment of patients with advanced NSCLC whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by FDA-approved test
- Adenocarcinoma segment accounted for largest revenue share in 2021, as it is most common type of lung cancer and has a high rate of incidence globally. About 40% of all cases of lung cancers are diagnosed with Adenocarcinoma. It usually occurs when lung cells proliferate abnormally to form a tumorous growth. Lung adenocarcinoma is most common cell type in females (smokers or non-smokers) and in non-smoking males. Incidence has been increasing in younger cohorts of males and females and has become a major cause of concern.
- Surgery segment revenue is expected to register a steady growth rate during the forecast period, as surgery performed at an early stage is the best time to cure NSCLC. Patients diagnosed with Stage 0 and Stage 1 NSCLC are provided surgical treatments such as segmentectomy and lobectomy which have proven success rates.
- Angiogenesis inhibitor accounted for a significant market revenue share in 2021. Segment growth is attributed to increasing demand for highly effective and more targeted therapies in both established as well as emerging economies such as the U.S., India, Japan, and Europe among others.
- Market in North America accounted for largest revenue share in 2021 due to increasing support from the U.S. Government for developing therapies and drugs to treat different types of cancer. Availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is also contributing to market growth.
- Market in Europe accounted for second-largest revenue share in 2021 due to increased R&D initiatives for development of advanced therapeutics. Moreover, presence of leading companies such as Novartis, AstraZeneca, Sanofi, and Roche are fueling growth of market.
- Major companies in global market report include Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, F.Hoffmann-La Roche Ltd, Merck KGaA, Sanofi, and Astellas Pharma Inc.
Get In detailed Research Study @ https://www.reportsanddata.com/report-detail/non-small-cell-lung-cancer-market
For the purpose of this report, Reports and Data has segmented NSCLC market based on histology, treatment, drug class, and region:
Histology Outlook (Revenue, USD Billion; 2019–2030)
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Adenocarcinoma
Treatment Type Outlook (Revenue, USD Billion; 2019–2030)
- Surgery
- Radiation
- Chemotherapy
- Targeted Therapy Drugs
Drug Class Outlook (Revenue, USD Billion; 2019–2030)
- Angiogenesis Inhibitor
- Epidermal Growth Factor Receptor Blocker
- Kinase Inhibitor
- Microtubule Stabilizer
- Folate Antimetabolites
- PD-1/ PD-L1 Inhibitor
Download Summary @ https://www.reportsanddata.com/download-summary-form/1475
Regional Outlook (Revenue, USD Billion; 2019–2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest Of MEA
Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/1475
Some points on how the report benefits stakeholders:
- The reports include historical (2019–2020) and forecast (2021–2030) data points, revenues, and CAGR in table, figure, and chart formats, with detailed and qualitative, supporting written information for each.
- Revenue break-up is provided for each segment in these formats for global, regional, and for each country in the respective region for each year between 2019 and 2030.
- The report contains insights regarding growth drivers, restraints, opportunities, trends, company profiles, strategic developments, expansion details, product launches, and various other aspects related to the market.
- The report contains data and information on customers, competitors, vendors/distributors, and other players and in the global marketplace.
- Market research analysis is vital for all crucial business strategies and can aid in numerous ways and to provide a clearer understanding about strategies being deployed by competitors, product launches, competitive analysis, technological advancements and various other factors that enhance sales of a firm or perhaps provide insights to focus on merger and acquisition as a strategy or enter into strategic agreements or joint ventures etc.
- The report contains company profiles of the top companies operating in the market along with their respective revenue and operating segments, geographical reach, market footprint, headquarters, growth rates, recent developments, product /services, expansion strategies, investments in expansion, and more.
Explore Latest Trending Research Reports By Reports and Data’s
Candidiasis Therapeutics Market , By Drug Type (Polyene, Azole, Echinocandin, Others), By Route of Administration (Injection, Ointment, Oral), By Anatomy Type (Oral, Vulvovaginal, Cutaneous, Invasive, Systemic), By End-use (Hospitals, Clinics, Retail Pharmacies, Drug Stores), and By Region Forecast To 2028
Zinc Pyrithione Market Size, Share And Industry Analysis By Grade (Industrial and Pharmaceuticals), By Application (Personal Care Products, Paints & Coatings, Pharmaceuticals, Biocides, and Others), and By Region Forecast to 2028
Short Bowel Syndrome Market By Diagnosis (Imaging Tests, Blood Tests, Fecal Fat Tests, Bone Density Test, Stool Exam, Physical Exam, Others), By Drug Type (Glucagon-like Peptide-2 (GLP-2), Glutamine, Zorbtive, GlutaSolve, Teduglutide (Gattex), Growth Hormone, Others), By Distribution Channel (Diagnostics Centers/Multispecialty Clinics, Hospitals, Hospital Pharmacies, Others), and By Region Forecast to 2028
Cancer Biological Therapy Market By Product Type (Vaccines, Cancer Growth Blockers, Monoclonal Antibodies, Blood Cell Growth Factors, Gene Therapy), By Application (Specialized Cancer Treatment Centers, Hospitals Pharmacies, Hospitals, Specialty Clinics, Research & Academic Laboratories, Others), and By Region Forecast To 2028
About Reports and Data\
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Read Latest Press Release @ https://www.reportsanddata.com/press-release/global-non-small-cell-lung-cancer-market